You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Antibody targeting of ADAM for treatment of triple negative breast cancer

    SBC: ADECTO PHARMACEUTICALS, INC.            Topic: NCI

    DESCRIPTION provided by applicant Triple negative breast cancers TNBCs account for of breast cancer deaths and lack targeted therapies Drs Sonenshein Mineva and Romagnoli and their co workers recently identified the non essential cell surface protein ADAM A Disintegrin and Metalloprotease as a pivotal promoter of breast tumor growth and metastasis and validated it as a target o ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  2. Development of a small molecule activator of integrin cell adhesion to enhance therapeutic responses to checkpoint blockade in cancer

    SBC: 7 Hills Pharma LLC            Topic: 102

    DESCRIPTION provided by applicant Recent FDA approvals of ipilimumab nivolumab and pembrolizumab which target checkpoint receptors cytotoxic T lymphocyte associated antigen CTLA and programmed death PD have ushered in a new era of cancer immunotherapy in metastatic melanoma Despite unprecedented overall survival benefits with combination therapy the incidence of complete respo ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  3. Novel Dental Adhesives to Prevent Recurrent Caries

    SBC: CuRE Innovations, LLC            Topic: NIDCR

    DESCRIPTION provided by applicant Bacterial related marginal decay is the top reason for failure and retreatment of resin based composite restorations RBCs Retreatment of these restorations costs both the patients and insurance companies billions of dollars per year The weak point of the system is the zone known as the hybrid layer where the adhesive bonds the RBC to the dentin There are ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  4. Nanoparticle Delivery System for Ewing Sarcoma Treatment

    SBC: NANOVALENT PHARMACEUTICALS INC            Topic: 102

    DESCRIPTION provided by applicant This Phase I STTR project seeks to demonstrate proof of principle that novel targetable nanoparticles can delivery therapeutic substances to human tumor cells and reduce tumor burden in metastatic cancer The concept for these nanoparticles is based on the polymerized liposome nanoparticle PLN that displays functional antibodies that target tumor cell surfac ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  5. Optimization of the Production and Isolation of the Novel Antifungal Occidiofungin

    SBC: Sano Chemicals, Inc.            Topic: NIAID

    DESCRIPTION provided by applicant Occidiofungin is a cyclic nonribosomally synthesized antifungal peptide with submicromolar fungicidal activity against a broad spectrum of fungi Occidiofungin is produced by the Gram negative bacterium Burkholderia contaminans From our structural characterization studies occidiofungin was determined to have a unique chemical composition Our studies have als ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  6. Lipidated Stable BAM8-22 Offers a Promising Therapeutic for Neuropathic Pain

    SBC: On Target Therapeutics, LLC            Topic: 106

    DESCRIPTION provided by applicant Neuropathic pain is a serious health problem that affects millions of people worldwide and occurs in as much as of the general population The management of neuropathic pain in patients is complex with an estimated of individuals refractory to existing analgesic therapies The aging population the diabetes epidemic and the significant cohorts of can ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  7. Blood based diagnostics for Alzheimer s Disease

    SBC: Amprion, Inc.            Topic: NIA

    DESCRIPTION provided by applicant This proposal is for a phase I II fast track project for the STTR program with the main goal to develop a blood test for Alzheimerandapos s disease AD diagnosis AD is the most common dementia in the elderly population and one of the leading causes of death in the developed world One of the main problems in AD is the lack of an early sensitive and objective ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  8. Novel mechanism for the treatment of epilepsy: New Vitamin K analogs target energetics and have low toxicity due to excellent specificity and low dose requirements compared to current therapies

    SBC: NEUROENE THERAPEUTICS INC            Topic: 106

    DESCRIPTION provided by applicant Epilepsy is the th most common neurological disorder with in people developing epilepsy the occurrence of more than one unprovoked seizure at some point in their lifetime Unfortunately of all patients have intractable medication resistant epilepsy Thus new anti epileptic drugs AEDs that target alternative mechanisms of action are needed ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  9. Targeted Polymerized Shell Microbubbles to Image Surgical Adhesions

    SBC: NANOVALENT PHARMACEUTICALS INC            Topic: NIGMS

    DESCRIPTION provided by applicant The long term goal of this Phase I STTR project is to develop a commercially viable ultrasound contrast reagent UCR that will allow the noninvasive identification of newly forming abdominal adhesions after surgery Successful implementation would have significant impact because we would remove the impediment to clinical testing of anti adhesion therapies and ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  10. Digital Gene Expression Analysis by 3’ End Sequencing

    SBC: BIOO SCIENTIFIC CORPORATION            Topic: 172

    DESCRIPTION provided by applicant A key application of deep sequencing is gene expression analysis at the RNA level commonly known as RNA seq Reads from RNA seq cover all regions of an mRNA sequence However sequences derived from the andapos end region are sufficient to indicate gene expression levels All andapos end sequencing methods have revealed that most eukaryotic genes display a ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government